ReNeuron boost as stem cell therapy for eye disease singled out for special Proactive Investors UKAIM-listed ReNeuron (LON:RENE) said it has received orphan drug status in the world s two biggest markets for its stem cell therapy to tackle a rare degenerative eye disease. The award by regulatory authorities in the US and Europe covers ReN003, [ ]
http://blog.zandcell.com/reneuron-boost-as-stem-cell-therapy-for-eye-disease-singled-out-for-special-proactive-investors-uk/?utm_source=rss&utm_medium=rss&utm_campaign=reneuron-boost-as-stem-cell-therapy-for-eye-disease-singled-out-for-special-proactive-investors-uk
Inga kommentarer:
Skicka en kommentar